ModerateProton pump inhibitor (PPI)×Synthetic steroid with estrogenic, progestogenic and weak androgenic activity
Updated · Methodology
Mechanism
In laboratory studies, tibolone had minimal effects on cytochrome P450 enzymes, but in people it moderately changed the pharmacokinetics of midazolam, a substance metabolised by the CYP3A4 enzyme. Interactions of tibolone with other CYP3A4 substrates therefore cannot be ruled out (Boltin SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In studies with human liver microsomes, rabeprazole was metabolised by CYP2C19 and CYP3A4 (Pariet SmPC, AEMPS), and a significant portion of the dose is converted to a thioether without enzymes (Aciphex label, US Food and Drug Administration, FDA). In a study with clarithromycin and amoxicillin, rabeprazole AUC rose by 11% and peak concentration by 34%, an increase not expected to produce safety concerns (Aciphex label, FDA). The documents do not say how much or in which direction tibolone could change rabeprazole levels. There is no effect the other way round: at the concentrations expected in people, rabeprazole neither induces nor inhibits CYP3A4 (Pariet SmPC, AEMPS).
Symptoms
The documents describe no symptoms linked to this combination. The most common adverse effects of rabeprazole are headache, diarrhoea, abdominal pain, weakness, flatulence, rash and dry mouth (Pariet SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Common adverse effects of tibolone include vaginal bleeding and discharge, breast tenderness, lower abdominal pain, thickening of the endometrium and weight gain (Boltin SmPC, AEMPS).
Management
No document contraindicates this combination or calls for a dose change because of it (Boltin and Pariet SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS; Aciphex label, US Food and Drug Administration, FDA). According to the tibolone SmPC, interactions with substances metabolised by the CYP3A4 enzyme cannot be ruled out, and rabeprazole is partly metabolised by this enzyme, but the SmPC gives no action for this situation (Boltin and Pariet SmPCs, AEMPS). During long-term rabeprazole treatment, especially beyond one year, the patient is reviewed regularly (Pariet SmPC, AEMPS). Proton pump inhibitors at high doses and for more than a year may modestly increase the risk of hip, wrist and spine fractures, mainly in older people or with other risk factors. People at risk of osteoporosis are managed according to current guidelines and need adequate vitamin D and calcium intake (Pariet SmPC, AEMPS). Tibolone is started only when menopausal symptoms adversely affect quality of life, and benefits and risks are reassessed at least once a year (Boltin SmPC, AEMPS). Bleeding and spotting are common in the first months of tibolone. If they continue after 6 months, start later or persist after stopping treatment, a gynaecological examination is carried out, which may include an endometrial biopsy, to exclude cancer (Boltin SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Tibolona, Boltin 2,5 mg (nº registro 60100), sección 4.5 (2021)– AEMPS, CIMA, nº registro 60100 (Boltin 2,5 mg comprimidos, Organon Salud), revisión 03/2021 (texto revisado 08/2020), secciones 4.4, 4.5 y 4.8
- AEMPS: Ficha técnica: Rabeprazol, Pariet 20 mg (nº registro 62462), sección 4.5 (2026)– AEMPS, CIMA, nº registro 62462 (Pariet 20 mg comprimidos gastrorresistentes, Janssen-Cilag), revisión 04/2026 (texto revisado 03/2026), secciones 4.4, 4.5, 4.8 y 5.2
- FDA: Aciphex (rabeprazole sodium) prescribing information (2026)– FDA, DailyMed setid 1eb38279-0237-4967-be7a-c53a826c1138 (Waylis Therapeutics), revisión 01/2026 (versión 3), secciones 7 y 12.3